UniQure AMT-130 BLA Filing After FDA Accepts 3-Year Data
uniQure AMT-130 BLA submission slated 3Q 2026 after FDA agreed a ~3-year analysis can support accelerated approval and news had lifted shares premarket
KEY TAKEAWAYS
- FDA agreed a roughly three-year Phase I/II analysis can be the primary basis for an accelerated BLA.
- uniQure intends to submit the BLA in 3Q 2026, pending final FDA meeting minutes.
- AMT-130 has RMAT designation, boosting prospects for priority review and expedited pathways.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
uniQure N.V. (NASDAQ: QURE) said in a June 17, 2026 press release that the FDA agreed a roughly three‑year analysis from its Phase I/II AMT‑130 program can serve as the primary basis for a Biologics License Application seeking accelerated approval. The company plans to file the BLA in the third quarter of 2026.
FDA Agreement and Filing Timeline
uniQure said the FDA’s feedback came during a recent Type B meeting, a formal discussion between the agency and sponsor on development programs. The company disclosed the meeting outcomes in a Form 8‑K filed with the Securities and Exchange Commission. It expects to receive final written minutes within 30 days and is guiding its regulatory plans based on the preliminary feedback.
The FDA agreed that the roughly three‑year analysis from uniQure’s Phase I/II AMT‑130 study can serve as the primary basis for an accelerated-approval BLA in Huntington’s disease. The company intends to submit the application in 3Q 2026.
Clinical Program and Regulatory Designations
AMT‑130 is an investigational gene therapy for Huntington’s disease, a progressive inherited neurodegenerative disorder. uniQure’s development program includes two multi-center, dose-escalating Phase I/II studies testing low and high doses with long-term follow-up. The filing will rely on data from these follow-ups.
The studies initially included a sham-surgery control arm, but uniQure said the regulatory analysis compares AMT‑130 with standard-of-care therapy rather than sham procedures. The company has previously disclosed clinical outcome and biomarker data but emphasized the FDA’s agreement on the three-year analysis as the BLA basis rather than new efficacy or safety details.
AMT‑130 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, which uniQure described as the first RMAT granted for Huntington’s disease. RMAT status offers intensive FDA guidance and may qualify a program for priority review and other expedited pathways. Under accelerated approval, sponsors typically must conduct post-marketing confirmatory studies to verify clinical benefit.
uniQure plans to proceed with the BLA submission as outlined, with near-term regulatory steps tied to reviewing the FDA’s final meeting minutes. After submission, the FDA will decide whether to accept the filing and then conduct a full review. Priority review is possible given the RMAT designation, and any accelerated approval would generally require post-marketing commitments to confirm benefit.
